Cadrenal Therapeutics, Inc. Common Stock (CVKD)

US — Healthcare Sector
Peers: MLYS  GPCR  CNTA  NVCT  SNTI  ZIVO  FHTX  QNRX  IKNA  ENOB  ELYM  HCWB  XCUR  CINGW  SABS  ANEB  MNPR  ANTX  MIRO  IKT  PMVP 

Automate Your Wheel Strategy on CVKD

With Tiblio's Option Bot, you can configure your own wheel strategy including CVKD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CVKD
  • Rev/Share 0.0
  • Book/Share 3.315
  • PB 3.7255
  • Debt/Equity 0.0
  • CurrentRatio 4.3174
  • ROIC -2.1483

 

  • MktCap 24288436.0
  • FreeCF/Share -5.5185
  • PFCF -2.3867
  • PE -2.5338
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.7155

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Cadrenal Therapeutics, Inc. Common Stock (CVKD)

  • IPO Date 2023-01-20
  • Website https://www.cadrenal.com
  • Industry Biotechnology
  • CEO Mr. Quang X. Pham
  • Employees 4
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.